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The role of tumor cell chemosensitivity test in second-line or third-
line chemotherapy in non-small cell lung cancer
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Background: In treatment of advanced non-small cell lung cancer, the 
effect of chemotherapy is limited and unpredictable. Especially in cases 
of recurrent or relapsed tumor, the choice of regimen is very restricted. 
This study was to determine whether the sensitivity test of chemothera-
peutic agents is valuable in choosing the drugs of the second-line or 
third-line treatment in the advanced non-small cell lung cancer.
Methods: In 11 patients, resistant to or relapsed after the ﬁrst-line or 
second-line chemotherapy, we got the tumor cells by the nine neck 
nodes or two bronchoscopic biopsies and did chemosensitivity test by 
the adenosine triphosphate-based chemotherapy response assay meth-
ods. The drugs tested were cisplatin, carboplatin, paclitaxel, docetaxel, 
gemcitabine, vinorelbine and irinotecan. We regarded the drug is sensi-
tive in cases the cell death rate was above 30%, and chose two drugs of 
higher cell death rates as chemotherapeutic agents. After two cycles of 
chemotherapy, the response was evaluated.
Results: The mean age of the patients was 54.9 year, and one patient 
was excluded in the ﬁnal analysis because the secondary tumor was 
proved as small cell lung cancer. Five patients were for the second-line 
and another ﬁve were for the third-line chemotherapy. Six tumors were 
sensitive to 3 drugs, 2 tumors were to two, and another two were to one 
agent. Cisplatin, gemcitabine, vinorelbine and irinotecan were sensitive 
in 5 cases respectively. Docetaxel was sensitive in 3 cases, paclitaxel 
and carboplatin were sensitive in 2 cases respectively. Regardless of the 
previous treatment, cisplatin kept the sensitivity in 4 of 8, gemcitabine 
in 2 of 3, and docetaxel in 1 of 3 cases. Complete response was found 
in 2 of 8 evaluable patients, and partial response was in 3, stable in 1, 
and disease progressed in 2 cases.
Conclusions: In cases of recurrent or resistant non-small cell lung can-
cer, chemosensitivity test would provide another options in choosing 
the chemotherapeutic agents. 
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Background: The identiﬁcation of molecular markers useful for che-
motherapy response assessment may help in treatment optimization of 
selected groups of patients that will beneﬁt from the therapy and help to 
improve the therapy results. Markers that would be useful for predic-
tive factors assessment in NSCLC are under investigation.
The aim of the study: Estimation of response to chemotherapy depend-
ing on BCL-2, BCL-x
L
, Survivin and P53 protein expression.
Material and Methods: The group of 60 consecutive patients that 
were admitted to The Oncology Center of Lublin Land and to Depart-
ment of Thoracic Surgery Medical University of Lublin was examined. 
The stage according to TNM was as follows: IIB - 26 cases (43,3%), 
IIIA - 34 cases (56,7%). Patients were treated with chemotherapy 
before planned surgery according to the schedule: cisplatin 30 mg/m2 
plus etoposid (PE) 100mg/m2 for three consecutive days, every 21 
days. The response to the therapy according to WHO was estimated. 
Protein expression was estimated by means of immunohistochemistry 
on parafﬁn tumor samples taken during surgery (the cut of was set on 
10% of positive cells). 
Results: Expression of BCL-2, BCL-x
L
, Survivin and P53 proteins was 
found in 20%, 81,7%, 90% and 53,3% of cases, respectively. The per-
centage of positive cells (positive cytoplasmic or nuclear signal) in 500 
tumor cells was estimated by semiquantitive method. Statistical analy-
sis showed signiﬁcant differences only in BCL-x
L
, and Survivin protein 
expression in response to chemotherapy. In patients that responded to 
the therapy we found less cells showing protein expression (p<0,05). 
There was no statistical signiﬁcant correlation between median P53 
protein expression and response to the chemotherapy, however low 
median per cent value of P53 positive cells was observed in patients 
that responded to the therapy.
Conclusion: High BCL-x
L
, and Survivin protein expression in tumor 
cells was found to be an important marker of lack of clinical response 
to the chemotherapy
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Impact of gender on median overall survival (MOS) in patients 
with advanced non-small cell lung cancer (NSCLC) treated with 
platinum-based chemotherapy- Single center experience
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Introduction: There is a debate on the impact of sex on survival of 
patients with advanced NSCLC. We retrospectively evaluated whether 
or not sex affects median overall survival (MOS) in patients with 
advanced NSCLC treated with 2nd or 3rd generation platinum-based 
regimens.
Patients and Methods: 230 patients with advanced NSCLC (un-
resctable IIIA/IIIB/IV) treated with 2nd or 3rd generation platinum-
based chemotherapy was retrospectively analyzed for the impact of 
gender differences on MOS. Confounding factors (i.e. median age, 
stage and pathology) were also evaluated in both sexes.
Results: 181 men and 49 women were included in this analysis. There 
was no statistically signiﬁcant difference in stage distribution (i.e. 
IIA/IIIB/IIIBw+IV) in both sexes (P=0.2). The difference in pathologic 
subtypes (undiff. NSCLC, Squam., Adenoca.) was statistically signiﬁ-
cant between women and men (15.1/9.4/75.5% and 25.6/31.8/42.6, 
respectively) (P =0.1/0.001/0.001). Mean age was 53.2 ± 11 in women 
and 59.7 ±11.7 in men (P<0.001). Although the median survival time 
was longer in women but it was not statistically signiﬁcant (13.7 m vs 
